FDA
approval
· 2023-03-31
FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
Summary
The FDA approved a supplemental application for SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide), a fixed-dose HIV-1 therapy from Janss…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for SYMTUZA (DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)